No Abstract BioWorld International CorrespondentProtAffin AG raised €14 million (US$18.3 million) in a Series B round to progress its early stage pipeline of novel, protein-based therapeutics that act by disrupting biological signaling between extracellular glycan structures and their protein ligands.The Graz, Austria-based company is adding 11 new staff on the strength of the new funding, boosting total headcount to 27 people.